Medpace CEO August Troendle sells $27.4m in company stock

August J. Troendle, CEO and President of Medpace Holdings Inc. (MEDP), divested a substantial portion of his company's stock, amounting to around $27.4 million, in two transactions in late September 2026. The stock experienced a 33% increase over the past six months, trading close to $619 per share. However, InvestingPro analysis indicates the shares are currently overvalued relative to their intrinsic value.

On September 23, Troendle sold 16,083 shares at an average price of $628.64 per share, ranging from $620.00 to $637.48. The following day, he sold an additional 27,833 shares at an average price of $621.33 per share, with individual transactions priced between $620.00 and $625.90. These sales generated a total of $27,403,895. Post-transaction, Troendle directly owns 389,456 shares of MEDP, with an additional 4,733,019 shares held indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.

He disclaims beneficial ownership except for any financial interest. For comprehensive analysis on MEDP's valuation, investors can refer to the Pro Research Report which includes 14 InvestingPro Tips. Recently, Medpace Holdings Inc. reported robust Q2 2026 results, exceeding expectations with diluted earnings of $4.25 per share and revenue of $707.3 million.

Revenue increased by 17.2% year-over-year, while diluted earnings per share rose by 37.1%. The company's revenue from new business awards also rose by 28.2% to $795.7 million, with a book-to-bill ratio of 1.13x. Additionally, Medpace's backlog grew to $3.0 billion, a 4.9% increase from the prior year. Following these results, BMO Capital raised its price target to $600 with a Market Perform rating, noting strong demand.

Conversely, TD Cowen lowered its target to $492, citing potential challenges in metabolic drug studies by 2027. Jefferies maintained a Hold rating with a $560 target, following a headquarters visit.